Investigating The Altered Landscape Of Enteric Viruses Causing Severe Gastroenteritis In Australian Children Following Rotavirus Vaccine Introduction
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
The rotavirus vaccines were introduced in Australia in 2007, decreasing rotavirus disease. Rotavirus strains naturally evolve during replication, however, high vaccine coverage in the population creates a new environment with different evolutionary pressures where strains not protected by the vaccines may emerge and become dominant. The diminished circulation of rotavirus may create an environment where other viruses capable of causing childhood gastroenteritis may increase.
Hepatitis B Virus Drug Resistance: Impact On The Immunisation Program
Funder
National Health and Medical Research Council
Funding Amount
$113,322.00
Summary
ñAntiviral drug-associated vaccine escape mutantsî have the potential to jeopardize the hepatitis B immunization program. Which particular viral mutations or combination of mutations that can directly affect the clinical outcome of infection, especially in the context of vaccine induced immunity, are not known. In this study we will identify the clinical sequelae and public health consequences arising from the selection of these mutants.
Mucosal Human Immunodeficiency Virus Vaccine Late Pre-clinical Evaluation
Funder
National Health and Medical Research Council
Funding Amount
$575,315.00
Summary
Despite many candidate vaccines entering clinical development for protection against HIV, none has yet been successful. This proposal centres on late preclinical development for a novel mucosal vaccine strategy for HIV, which combines a preclinically-proven approach to generating strong T cell immune responses, with an existing approach to generating broadly neutralising antibody responses to HIV. Proof of synergy between these approaches will lead directly to clinical development.
Pre-clinica Evaluation Of A Novel HIV-1 Vaccine Statrgy
Funder
National Health and Medical Research Council
Funding Amount
$528,440.00
Summary
Recently, we have designed two mucosal HIV vaccine strategies that temporary block hormone-like molecules IL-4/IL-13 at the vaccination site inducing excellent antibody and killer T cell immunity with protective efficacy in small animals. This project aims to evaluate the safety and efficacy of these novel HIV mucosal vaccines prior to clinical evaluation.
Prophylactic Vaccine To Prevent Cytomegalovirus Disease
Funder
National Health and Medical Research Council
Funding Amount
$436,360.00
Summary
This project is aiming to develop a prophylactic vaccine against a common herpesvirus which has been linked to the birth defects in new born babies and significant morbidity and mortality in transplant patients. In this project we are testing a novel nanoparticle-based vaccine formulation which stimulates the immune system with single injection and the immunity induced is sustained for long-term.